Bone Growth Stimulators act as a constant-current source by passing more energy to the healing bone surface through pulsed ultrasound, which helps the bone heal more quickly. According to BlueQuark the Global Bone Growth Stimulator Market is expected to grow considerably during the forecasted period. Factors such as the increasing incidence of trauma and accident cases worldwide are expected to drive the Bone Growth Stimulator Market in the forecasted period. Further, the growing number of bone fracture cases and the productiveness of external bone growth stimulators in healing fractures are expected to drive the Bone Growth Stimulator Market in the forecasted period. Furthermore, an increase in the inclination of patients toward minimally invasive & non-invasive surgical treatments and an increase in platelet-rich plasma and bone morphogenetic protein is expected to drive the Bone Growth Stimulator Market in the forecasted period. However, bone growth stimulators can be expensive, especially for advanced or specialized devices. This high cost can limit their accessibility and adoption, particularly in regions with hampering healthcare budgets or veterinary practices with budget constraints.

A growing incidence of trauma and accident cases worldwide is considered one of the major factors likely to increase the demand for the market. Osteoarthritis (OA) is the most common form of arthritis that frequently occurs in the hands, hips, and knees. It is known as degenerative joint disease or wear and tear arthritis in individuals suffering from OA. The cartilage and bones of the typical breakdown result in disability. The rising incidences of diseases such as arthritis and the increasing number of trauma injury and fracture cases drive the demand for bone growth stimulators to boost the healing process. The senior population is highly susceptible to arthritis and osteoporosis, and physicians use ultrasound bone growth stimulators, such as devices, bone grafts, and substitutes, to heal bones. The rise in prevalence and increase in the burden of orthopaedic diseases has led to an increase in the patient pool undergoing minimally invasive surgeries globally. This has resulted in a high need for bone growth stimulators. The high chances of bone marrow transplants and bone cancers are also elevating the need for bone stimulators. The bulk of osteoarthritis increases with age. Therefore, an increase in most orthopaedic disorders is anticipated to boost the bone growth stimulators market during the forecast period. Healthcare practitioners are carrying out advanced bone biology research to increase patient outcomes. They are also expanding the use of bone densitometers, advanced equipment, and enhanced X-ray technology to measure bone loss. The Bone growth stimulation devices held the largest market share due to the increasing ageing population across the globe, which is more susceptible to bone fractures and related ailments, increasing the demand for these devices. Advancements in medical technology have developed the growth of more structured and sophisticated bone growth stimulator devices, improving their effectiveness and acceptance. Moreover, the increasing incidence of sports injuries and road accidents has further grown the adoption of bone growth stimulators as an additional therapy for faster healing.

North America dominates the global bone growth stimulator market owing to the strong base of healthcare facilities, the strong existence of major players, the healthcare infrastructure, and the large pool of people with bone diseases and disorders. Asia-Pacific is predicted to witness significant growth during the forecasted period of 2023 to 2030 owing to the increase in government initiatives to promote healthcare, the increasing health awareness among the people and rising demand for advanced medical technology for skin care, the large population pool, and the surging demand for quality healthcare in the region. The increasing adoption of MI and robotic surgeries is one of the vital bone growth stimulators that market trends are expected to gain traction in the forthcoming years. The rising number of health complications associated with traditional open surgeries is boosting the growth and adoption of MI surgeries that require a short hospital stay. Conventional open surgeries often cause several post-surgical complications, such as pain, blood clots, fatigue, muscle atrophy, and infections.

Consequently, the enhanced surgical precision, minimal error, and difficulties robots offer will drive the demand for electric bone stimulators. The need for minimally invasive procedures and Ultrasonic Osteogenesis Stimulators has increased due to the advantages offered by the methods. Non-invasive bone growth stimulators provide various benefits, such as fewer operative complications, shorter hospitalization, smaller cosmetic incisions, reduced postoperative care, and quicker recovery, which is fueling the growth of the Bone Growth stimulator market. The increasing prevalence of arthritis problems, rise in accidental bone fracture or damage, bone surgical repair, and the rising demand for bone growth stimulators to heal bone are some of the major factors propelling revenue growth of the bone growth stimulators market.

An increase in the geriatric population and a surge in various chronic problems such as obesity, vascular diseases, Diabetes, and renal or kidney disorders can result in bone weakening and require bone healing using bone growth stimulators and thus contribute to revenue growth of the global bone growth stimulators market. Technological advancements in the bone growth stimulators and significant critical players in the market focusing on cost minimizing of bone growth stimulators products resulting in the removal of overall treatment cost, improved healthcare facilities, and a surge in government investment in the healthcare sector will observe lucrative growth opportunities in the forecasted period.

The market key players are Zimmer Biomet, Bioventus, Synergy Orthopedics, Ito Co., Ltd., and Boston Scientific Corporation.

In May 2022, Orthofix Medical Inc. acquired FDA premarket approval for the AccelStim Bone Growth Stimulation Device. This approval shows that the device has met the regulatory demand and can now be marketed and sold in the United States. The AccelStim Bone Growth Stimulation Device is predicted to provide advanced therapeutic options for promoting bone healing and treating fractures effectively.

In March 2022, the collaboration announced the competition of ZimVie, its offshoot. The separation represents an important step forward in Zimmer Biomet's active portfolio management.

Our Global Bone Growth Stimulator Market report provides deep insight into the current and future state of the market across various regions. Also, the study comprehensively analyzes the Bone Growth Stimulator market by segments based on the Product (Bone Growth Stimulation Devices, Bone Morphogenetic Proteins, Platelet-Rich Plasma), Application (Spinal Fusion Surgeries, Delayed Union and Non-union Bone Fractures, Oral and Maxillofacial Surgeries), End-User (Hospitals and Clinics, Home Care, Academic and Research Institutes and CROs), and by Geography (Asia Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints and the impact of COVID-19 on market growth in detail. The study covers & includes emerging market trends, market developments, market opportunities, market size, market analysis, market dynamics, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of prominent companies, including their market share and projects.